TeneoBio | Evaluate

Teneo’s heavy chain success keeps on delivering

Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.

Amgen doubles down on bispecifics, courtesy of Teneobio

Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.

November 23, 2020

Ash 2020 preview – Novartis touts its Tasigna follow-on

Pivotal data at the upcoming Ash conference make Novartis’s asciminib one of the highlights for oncology watchers.

February 12, 2019

Abbvie comes to the multiple myeloma party late